Australian & New Zealand Childrens Haematology/Oncology Group
Study Title
A Phase 3 Open-label, Multicenter Study of the Long-term Safety and Efficacy of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein (rFVIIIFc-VWF-XTEN; BIVV001) in Previously Treated Patients With Severe Hemophilia A
Protocol ID
LTS16294
Disease (Sub Disease)
Hemophilia
Diagnosis Stage
Previously treated
Location
QLD
Sponsor
Bioverativ, a Sanofi company
Links
Trial Status
Open
Sites
Queensland Children's Hospital
Study Type
Treatment
Phase
Phase 3
Age Eligibility
Child, Adult, Older Adult
International registry ID's
NCT04644575
| Study Title | A Phase 3 Open-label Multicenter Study of the Long-term Safety and Efficacy of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein (rFVIIIFc-VWF-XTEN; BIVV001) in Previously Treated Patients With Severe Hemophilia A |
|---|---|
| Protocol ID | LTS16294 |
| Disease (Sub Disease) | Hemophilia |
| Diagnosis Stage | Previously treated |
| Location | QLD |
| Sponsor | Bioverativ, a Sanofi company/ |
| Links | https://clinicaltrials.gov/ct2/show/NCT04644575 |
| Trial Status | Open |
| Trial Open Date | 23/02/2022 |
| Sites | Queensland Children's Hospital |
| Study Type | Treatment |
| Phase | Phase 3 |
| Age Eligibility | Child, Adult, Older Adult |
| International registry ID's | NCT04644575 |